Shortage of remdesivir drives Taiwan to consider using alternative drug

As remdesivir has reportedly been in great demand in US, Taiwan only received 78 doses out of 2,000-dose order

Taiwan News
Date: 2020/08/03
By: George Liao, Taiwan News, Staff Writer

dexamethasone (Wikipedia photo)

TAIPEI (Taiwan News) — Faced with a shortage of remdesivir, Taiwan’s Central Epidemic Command Center (CECC) said on Monday (Aug. 3) that it is considering the adoption of dexamethasone as an alternative drug, indicating that it may include it in the treatment guidelines for COVID-19 patients.

In order to ensure that COVID-19 patients with severe symptoms can be treated with remdesivir in the event of a second wave of the virus, the Taiwan Food and Drug Administration (FDA) approved the use of remdesivir at the end of May, ordering 2,000 doses to be delivered before the end of July, per CNA.

As remdesivir has reportedly been in great demand in the U.S., Taiwan only received 78 doses out of the 2,000-dose order, causing public health concerns.

The U.S. government announced at the end of June that it would purchase 500,000 doses of remdesivir, an amount equal to Gilead Sciences Inc.’s total output for July, August, and September.    [FULL  STORY]

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy

This site uses Akismet to reduce spam. Learn how your comment data is processed.